TIS 0.00% 0.0¢ tissue therapies limited

I agree with you, Advisor. I notice they are still producing...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 1,092 Posts.
    lightbulb Created with Sketch. 1576
    I agree with you, Advisor. I notice they are still producing VitroGro at the rate of $1M per quarter (cost). I would expect TIS will get 10 times this cost at least when it starts to sell, after payments to partners. Remember that very little is used in one treatment, so cost is relatively low. Receivables will become significant within a few months, and this could be the basis for a small loan to cover cash flow, until receivables converts to cash. I think their partner also has a service where they can provide for such a loan?

    I would rather a few months delay in US trials rather than a diluting cap raising.
 
watchlist Created with Sketch. Add TIS (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.